Allogene Therapeutics Q4 Earnings Call Highlights

Chief Medical Officer Dr. Zachary Roberts described ALPHA3 as the first randomized lymphoma study designed to test whether early minimal residual disease (MRD)-guided consolidation with an allogeneic CAR T can prevent relapse. In the trial, patients who achieve remission after standard first-line therapy undergo ctDNA testing; those who are MRD-positive are randomized to observation or treatment with cema-cel.Chang said Allogene is prioritizing programs where it believes allogeneic CAR T’s advantages—scalab ...